US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% WDC $415.29 ▲+0.00% TSLA $370.59 ▲+0.00%
FinancialContent

Articles published by Celcuity Inc.

News headline image
Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer
From Celcuity Inc.
Via AccessWire
Tickers CELC
News headline image
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences
From Celcuity Inc.
Via AccessWire
Tickers CELC
News headline image
Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates
From Celcuity Inc.
Via AccessWire
Tickers CELC
News headline image
Celcuity Inc. Announces $100 Million Private Placement
From Celcuity Inc.
Via AccessWire
Tickers CELC
News headline image
Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call
From Celcuity Inc.
Via AccessWire
Tickers CELC
News headline image
Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor Conferences
From Celcuity Inc.
Via AccessWire
Tickers CELC
News headline image
Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates
From Celcuity Inc.
Via AccessWire
Tickers CELC
News headline image
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2021 Financial Results and Webcast/Conference Call
From Celcuity Inc.
Via AccessWire
Tickers CELC
News headline image
Celcuity to Participate in the Cowen 42nd Annual Health Care Conference
From Celcuity Inc.
Via AccessWire
Tickers CELC
News headline image
Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate Update
From Celcuity Inc.
Via AccessWire
Tickers CELC
News headline image
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer Symposium
From Celcuity Inc.
Via AccessWire
Tickers CELC
News headline image
Celcuity to Present at the 2021 San Antonio Breast Cancer Symposium
From Celcuity Inc.
Via AccessWire
Tickers CELC
News headline image
Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process Development
From Celcuity Inc.
Via AccessWire
Tickers CELC
News headline image
Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance(R) (palbociclib) for Planned Phase 3 Clinical Trial
From Celcuity Inc.
Via AccessWire
Tickers CELC
News headline image
Celcuity to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences
From Celcuity Inc.
Via AccessWire
Tickers CELC
News headline image
Celcuity Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
From Celcuity Inc.
Via AccessWire
Topics Intellectual Property
Tickers CELC
News headline image
Celcuity Inc. Schedules Release of Third Quarter 2021 Financial Results and Webcast/Conference Call
From Celcuity Inc.
Via AccessWire
Tickers CELC
News headline image
Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases
From Celcuity Inc.
Via Business Wire
Tickers CELC
News headline image
Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
From Celcuity Inc.
Via AccessWire
Tickers CELC
News headline image
Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference
From Celcuity Inc.
Via AccessWire
Tickers CELC
News headline image
Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast
From Celcuity Inc.
Via AccessWire
Tickers CELC
News headline image
Celcuity to Participate in the William Blair Biotech Focus Conference
From Celcuity Inc.
Via AccessWire
Tickers CELC
News headline image
Celcuity Announces Pricing of Follow-on Offering
From Celcuity Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers CELC
News headline image
Celcuity Announces Launch of Follow-on Offering
From Celcuity Inc.
Via AccessWire
Topics Regulatory Compliance
Tickers CELC
News headline image
Celcuity Announces Appointment of Dr. Igor Gorbatchevsky as VP of Clinical Development and Jill Krause as VP of Clinical Operations
From Celcuity Inc.
Via AccessWire
Tickers CELC
News headline image
Celcuity Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update
From Celcuity Inc.
Via AccessWire
Tickers CELC
News headline image
Celcuity Inc. Schedules Release of First Quarter 2021 Financial Results and Webcast
From Celcuity Inc.
Via AccessWire
Tickers CELC
News headline image
Celcuity Presents Data at AACR Annual Meeting Assessing Gedatolisib, a pan-PI3K/mTOR Inhibitor, in HER2-negative Breast and Ovarian Cancer Patient Tumors with Hyperactive RAS Network Signaling
From Celcuity Inc.
Via AccessWire
Tickers CELC
News headline image
Celcuity Reports Preliminary Data from Phase 1b Trial of Gedatolisib plus Ibrance® and Endocrine Therapy for Patients with ER+/HER2- Metastatic Breast Cancer and Provides Corporate Update
From Celcuity Inc.
Via Business Wire
Tickers CELC
News headline image
Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer
From Celcuity Inc.
Via Business Wire
Tickers CELC